ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1844

Disease-Associated Macrophages Express an Injury-Associated Gene Program and Localize to Distinct Compartments in Proliferative and Mixed Histologic Classes of Lupus Nephritis

Paul Hoover1, Rollin Leavitt2, Jill Buyon3, Jennifer Anolik4, Jennifer Barnas5, Judith James6, Joel Guthridge6, Michelle Petri7, Betty Diamond8, Soumya Raychaudhuri1, Nir Hacohen9, Anne Davidson10 and Arnon Arazi11, 1Brigham and Women's Hospital, Boston, MA, 2Broad Institute, Boston, MA, 3NYU Grossman School of Medicine, New York, NY, 4University of Rochester Medical Center, Rochester, NY, 5University of Rochester, Rochester, NY, 6Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Johns Hopkins University School of Medicine, Timonium, MD, 8The Feinstein Institutes for Medical Research, Manhasset, NY, 9Broad Institute, Cambridge, MA, 10Feinstein Institutes for Medical Research, Manhasset, NY, 11The Feinstein Institutes for Medical Research, Manhasset

Meeting: ACR Convergence 2025

Keywords: genomics, Lupus nephritis, macrophages, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1830–1854) Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: In collaboration with the AMP-RA/SLE network, we identified disease-associated macrophages (D-Macs) in kidney biopsies from 155 patients with active lupus nephritis (LN) and 30 controls, using single-cell RNA sequencing of ~25,000 myeloid cells (Fig. 1A, B). D-Macs comprised several macrophage subsets and expressed an injury-associated gene program, including TREM2, CD63, CTSD, APOE, SPP1, GPNMB, CD9, and FABP5 (Fig. 1C), which are conserved across monocytes and macrophages in other injured tissues. D-Macs showed positive correlation with the ISN/RPS activity index and were more prevalent in proliferative and mixed histological classes (III/IV±V) compared to the pure membranous class (V) or healthy individuals (not shown). In this follow-up study, we explored the origins and significance of D-Macs in proliferative/mixed LN.

Methods: We analyzed kidney biopsies from LN patients and controls using single-cell RNA sequencing to identify distinct cell populations. Spatial transcriptomics was performed with a custom gene panel to map myeloid subtypes in FFPE kidney samples. We also examined transcriptomic responses to putative nephritic glomerular factors plus M-CSF in healthy CD14 monocytes using flow cytometry and RNA sequencing.

Results: Bioinformatic analysis suggested that D-Macs likely differentiate in situ from infiltrating monocytes or resident macrophages, indicating a process of “convergent differentiation” where blood and tissue myeloid cells adopt similar transcriptional profiles in response to factors from diseased kidneys (Fig. 1D-G). To gain further insight into D-Mac differentiation and function, we mapped each D-Mac subset alongside other myeloid populations across renal compartments and in relation to lesions in FFPE sections from 6 LN patients with proliferative or mixed histologic classes (mean ISN/RPS activity = 13.5; S.D = 5.8) and 2 controls. Certain D-Mac subsets were statistically enriched in glomeruli with proliferative lesions (Glomerular D-Macs), while others were mainly found in the tubulointerstitium (Tubulointerstitial D-Macs) (Fig. 2), suggesting that distinct D-Mac subsets may differentiate from different precursors in a compartment-specific manner.To determine whether factors from nephritic glomeruli drive D-Mac differentiation from infiltrating CD14+ or CD16+ monocytes, we screened 40 inflammatory mediators identified through single-cell data, spatial transcriptomics, histology, and literature review. Results showed that several glomerular factors—such as immune complexes with resiquimod, cell debris, and TGF-β—promoted the induction of D-Mac-like states, including an injury-associated gene program similar to that observed in patients, from both CD14+ (Fig. 3) and CD16+ (not shown) monocyte precursors.

Conclusion: Our findings highlight key glomerular mediators in proliferative lupus nephritis that may promote D-Mac differentiation from infiltrating monocytes. They support the idea that distinct monocyte states respond similarly to nephritic factors, converging on a shared cellular phenotype. Ongoing studies are focused on elucidating the functional roles of these cells.

Supporting image 1Fig. 1. (A-C) UMAP of single-cell analysis of myeloid cells labeled by clusters (A), case vs. controls (B), or average expression of injury associated genes. Black dotted line outlines the D-Mac clusters. (D-G) Assessing the feasibility of differentiation of monocytes and RMs into DMac clusters. The shortest paths from each putative origin into each DMac cluster is shown based on the results of trajectory analysis using partition based graph abstraction (PAGA) (PMID 30890159). Edges colored in red area also supported by the colocalization analysis presented below in Fig. 3. Paths originating from (D) CD16+ nonclassical monocytes (cluster M2); (E) CD14+ classical monocytes (cluster M3); (F) Lyve1+ RMs (cluster M9); (G) Lyve1- RMs (cluster M0).

Supporting image 2Fig. 2. Specific D-Mac subsets localize to glomeruli or tubulointerstitial regions of tissue. (A) Top panel shows example biopsy from patient with cass IV+V, activity 16/24 and chronicity 5/12. Bottom panel shows (B) areas of kidney in our analysis and (C) quantification of enrichment (red), depletion (blue), and statistical significance (asteriks) across indicated areas from 6 patients and 2 controls.

Supporting image 3Fig. 3. CD14 monocytes were stimulated with M-CSF alone or with the indicated factors and subject to single cell RNA-seq to measure the average expression of the injury associated score (genes in Fig. 1C).


Disclosures: P. Hoover: None; R. Leavitt: None; J. Buyon: Artiva Biotherapeutics, 2, Biogen, 2, Bristol-Myers Squibb(BMS), 2, Celgene, 2, CLIMB Bio Operating, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Related Sciences, 2, UCB, 2; J. Anolik: None; J. Barnas: None; J. James: GlaxoSmithKlein(GSK), 2, Progentec, 5; J. Guthridge: None; M. Petri: Amgen, 2, AnaptysBio, 2, Annexon Bio, 2, AstraZeneca, 2, 5, Atara Biosciences, 2, Aurinia, 2, 5, Autolus, 2, Bain Capital, 2, Baobab Therapeutics, 2, Biocryst, 2, Biogen, 2, Boxer Capital, 2, Cabaletto Bio, 2, Caribou Biosciences, 2, CTI Clinical Trial and Consulting Services, 2, CVS Health, 2, Dualitybio, 2, Eli Lilly, 2, 5, EMD Serono, 2, Emergent, 2, Escient Pharmaceuticals, 2, Exagen, 5, Exo Therapeutics, 2, Gentibio, 2, GlaxoSmithKlein(GSK), 2, 5, iCell Gene Therapeutics, 2, Innovaderm Research, 2, IQVIA, 2, Janssen, 5, Kezar Life Sciences, 2, Kira Pharmaceuticals, 2, Nexstone Immunology, 2, Nimbus Lakshmi, 2, Novartis, 2, Ono Pharma, 2, PPD Development, 2, Proviant, 2, Regeneron, 2, Seismic Therapeutic, 2, Senti Biosciences, 2, Sinomab Biosciences, 2, Steritas, 2, Takeda, 2, Tenet Medicines, 2, TG Therapeutics, 2, UCB, 2, Variant Bio, 2, Worldwide Clinical Trials, 2, Zydus, 2; B. Diamond: None; S. Raychaudhuri: Bonito, 1, Bristol-Myers Squibb(BMS), 1, Janssen, 1, Mestag, 1, 8, Nimbus, 2, Pfizer, 1, Sonoma, 1, 8, Visterra, 6; N. Hacohen: None; A. Davidson: None; A. Arazi: None.

To cite this abstract in AMA style:

Hoover P, Leavitt R, Buyon J, Anolik J, Barnas J, James J, Guthridge J, Petri M, Diamond B, Raychaudhuri S, Hacohen N, Davidson A, Arazi A. Disease-Associated Macrophages Express an Injury-Associated Gene Program and Localize to Distinct Compartments in Proliferative and Mixed Histologic Classes of Lupus Nephritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/disease-associated-macrophages-express-an-injury-associated-gene-program-and-localize-to-distinct-compartments-in-proliferative-and-mixed-histologic-classes-of-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-associated-macrophages-express-an-injury-associated-gene-program-and-localize-to-distinct-compartments-in-proliferative-and-mixed-histologic-classes-of-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology